Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Checkpoint blockade plus radiation in relapsed or refractory malignant lymphoma
2021-001270-34Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab and pembrolizumab in lymphosarcoma, sponsored by Radboud University Medical Center. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
lymphosarcoma
Beyond the preview
Go deeper on 2021-001270-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001270-34.